Company Overview of Xenoport, Inc.
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders in the United States. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase III clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is...
3410 Central Expressway
Santa Clara, CA 95051
Founded in 1999
Key Executives for Xenoport, Inc.
Co-Founder and Vice President of Discovery Biology
Chief Financial Officer and Senior Vice President of Finance
Senior Vice President of Regulatory Affairs & Quality
Chief Medical Officer and Senior Vice President of Clinical Development & Medical Affairs
Chief Patent Counsel and Vice President
Compensation as of Fiscal Year 2017.
Xenoport, Inc. Key Developments
XenoPort, Inc. Files Form 15
Jul 15 16
XenoPort, Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of par value $0.001 per share under the Securities Exchange Act of 1934, as amended.
Xenoport, Inc. To Be Delisted From NASDAQ
Jul 6 16
As previously disclosed, on May 21, 2016, Xenoport, Inc. (the company) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Arbor Pharmaceuticals, LLC. On July 5, 2016, in connection with the consummation of the Offer and the Merger, the Company (i) notified the NASDAQ Global Select Market (“NASDAQ”) of the consummation of the Merger and (ii) requested that NASDAQ file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company also intends to file with the SEC a Form 15 requesting that the Company’s reporting obligations under Section 13 and 15(d) of the Exchange Act be suspended.
Xenoport, Inc. Announces Executive Changes
Jul 5 16
Xenoport, Inc. announced in connection with the Merger and as contemplated by the Merger Agreement, at the Effective Time, each of John G. Freund, Dennis M. Fenton, Catherine J. Friedman, Jeryl L. Hilleman, William J. Rieflin and Wendell Wierenga voluntarily resigned from and ceased serving on the company's board of directors (the Board) and from all committees of the Board on which such directors served. In accordance with the terms of the Merger Agreement, the director of Purchaser immediately prior to the Effective Time, Edward J. Schutter, became the sole director of the Surviving Company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|